VEGFA and cancer: The inflammatory response, through increased release of TF, von Willebrand factor, plasminogen activator inhibitor (PAI-1), and VEGF induced by endothelial cells, together with a down-regulation of thrombin activity and the protein C system, can lead to a procoagulant phenotype in patients with cancer.